TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of patients developing acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Upper limbs movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG brain response to targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vestibular testing outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morning ocular itching diary scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of infusion reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Grade III/IV histological response in tumor specimen rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Absence of subretinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Severity score for critical coronavirus pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Symptom Severity Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence rate of new-onset Type 2 Diabetes (T2DM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence rate of new-onset Hyperlipidemia (HLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of chronic wound colonization with resistant/prevalent microorganisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Radiation Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Overall CLUE Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall CLUE Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remote end-organ perfusion and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in VM-PATHI Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the plasma concentration-time curve (AUC) from time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of ertugliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-PCP communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Achieving ACR70 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PSA response achieving stable nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: monetary cost of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pathologic Complete Response (pCR) of the Primary Tumor in the Breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: RUST Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of occupational stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Discontinuation due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Raw broccoli intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to try raw broccoli
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of taste exposures to raw broccoli
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Process outcome
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of new cavitated or incipient carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowest dose of droxidopa to increase seated SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hSBA geometries mean titres (GMTs) against relevant MenB strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 4 fold increase in hSBA against relevant MenB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hSBA titres >1:4 against relevant MenB strains at Visit3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cholesterol and triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mobilization of bone marrow derived liver associated stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in IIEF scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Simulated Scenarios Where an Antibiotic Was Not Prescribed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of GPs Completing the First Questionnaire
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Levels of sodium channel splicing variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with abnormal fetal growth or amniotic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change From Baseline in Percent-predicted FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Marginal Bone height changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of chromosomal abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensation levels during GES treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceptability and comfort of sensations during treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increased regional and global myocardial contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased myocardial perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in kinome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in kinome between responders and non-responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV end systolic volume (LVESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV end diastolic volume (LVEDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV-ejection fraction (LV-EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the percent of closed pockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Japanese Encephalitis Viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Episodes of delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 2 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics (AUC of RPT Over 24 Hours Post-dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Score from IDS-C30
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: COVID-19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Smoking Abstinence Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in systolic OBPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood pressure at discharge from PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in respiration rate at discharge from PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in pulse at discharge from PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in oxygen saturation at discharge from PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Insulin independence post transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mGluR5 availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synaptic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Best Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Vital sign changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical examination changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical laboratory test changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EKG changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficiency of the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug use at 6 (12) months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Days in work or education
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of drug-free friends at 6 (12) months
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Six Minute Step Test Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARDS development
Endpoint domain: Mortality/survival
Primary endpoint: ARDS survival
Endpoint domain: Mortality/survival
Primary endpoint: maximum tolerated dose (MTD) or maximum feasible dose (MFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Oxycodone tablets
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of hospitalizations for worsening cardio-respiratory symptoms
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cognitive Assessment: TMT
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Assessment: EOWVT Standard Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Assessment: CVLT
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Elastin content in tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Measure: Utilizing McGill Quality of Life Survey and FACT-B Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient Rated Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer Treatment Related Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of healing of donor sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported perception of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Potential clinical complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Serum 25-Hydroxyvitamin D Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microbiological analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality and quantity of wound discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Asthma Control Test (ACT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Oral Mucositis (Grade >/= 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with low birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sagittal Imbalance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued Radium-223 Dichloride Treatment Due to Treatment Emergent AEs or Death
Endpoint domain: Adverse events/effects
Primary endpoint: Trough Forced Expiratory Volume In One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Affective Dimension Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall tumor response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Physical Activity in Daily Life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bergen Burnout Indicator (BBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Steroid Usage Quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steroid Usage Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral Forearm bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of non-pedunculated keloids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation or Suicidal Behavior Item at Any Visit
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Vital Signs Parameter - Supine Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anticoagulant control measured by time in the therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Concentration-Time Curve From Time Zero Up to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined effective rate of blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined effective rate of plasma homocysteine reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Unpleasantness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional difficulty
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Absolute bioavailability of orally administered folic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Folate levels in plasma and RBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change From Baseline in Eosinophils in Induced Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in intensity of rhinosinusitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial Cell Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duodenogastric reflux index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GH and IGF-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acromegaly symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Indices of insulin secretion & sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline in depressive symptom scores at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral blood flow (CFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cerebral oxygen saturation (SO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cocaine use
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participant Fathers Self-reporting Engagement in Risky Sexual Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The Number of Participant Fathers Self-reporting Experiences of Intra-partner Violence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: The Number of Days Participant Fathers Reported Drinking in the Past 90 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of IGN002
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients who gave their consent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Grade II-IV acute graft versus host disease (aGVHD) or death
Endpoint domain: Mortality/survival
Primary endpoint: Detectable DTCs/CTCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clotting rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Emotional Recognition Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Paired Associates Learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rapid Visual Information Processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stop Signal Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Spatial Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Solicited Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of hair regrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in fovea avascular zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in retinal vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in choroidal vascular perfusion density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in nutrition adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of subjects reporting adequate relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Colonization at Day 1 Swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Colonization at Day 3 Swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Colonization at Day 7 Swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time spent on medications used to increase blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain level variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areal lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Energy Intake Compensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Viral Load < 400 Copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in haemoglobin A1c (HbA1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decreased brain responses to high-carbohydrate food cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bladder tissue evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes